pADL-20c Phagemid Vector

Product Description

pADL™-20c is a phagemid vector designed for phage display on the N-terminal side of the protein III of the filamentous bacteriophage M13 or equivalent. This vector contains a PelB leader sequence for expression in the periplasm, a double-SfiI/BglI cloning site to introduce scFvs or Fab fragments, a HIS tag for purification and an amber codon located before the full-length copy of the gene III sequence. On non-suppressive bacterial strains, free scFvs or Fab fragments are produced in the periplasm where they can be assayed for binding or purified for further testing. Expression of the fusion is under the control of a lac promoter that has been adjusted at a level comparable to the widely used phagemid pCOMB3.

Vector Map

Cloning Site

Applications

• Phage display at the N-terminal side of gene III protein of the filamentous bacteriophage.
• scFv and Fab display.
• Free scFv or Fab expression.

Specifications

General characteristics:

• Plasmid Size: 3930
• Promoter: lac promoter
• Leader Peptide: PelB
• Cloning Site: double-BglI/SfiI, NotI-SpeI
• Purification: HIS tag
• Fusion Protein: full length gene III protein and conditional amber stop codon
• Selection: ampicillin
• Replication: oriF1, pMB1

Physical Characteristics:

• Concentration: 0.5 µg/ µl
• Product Size: 10 µg
• Buffer: DNA Conservation Buffer (Tris/HCL 5 mM, EDTA 0.1 mM, pH 8.5, sterile)
• Storage Temperature: -20°C

Related Products

As helper phage for the preparation of virions we recommend Interference-Resistant Helper Phage CM13.

Citations

1. Stefan M.A., Light Y.K., Schwedler J.L., McIlroy P.R., Courtney C.M., Saada E.A., Thatcher C.E., Phillips A.M., Bourguet F.A., Mageeney C.M., McCloy S.A., Collette N.M., Negrete O.A., Schoeniger J.S., Weilhammer D.R., Harmon B. (2021). Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies. MAbs. 13(1):1958663.

2. Huo J., Le Bas A., Ruza RR. et al. (2020). Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol., 27(9):846-854.

3. He L., Lin X., de Val N., Saye-Francisco K.L., Mann C.J., Augst R., Morris C.D., Azadnia P., Zhou B., Sok D., Ozorowski G., Ward A.B., Burton D.R., Zhu J. (2017). Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer. Front Immunol., 8:1025.

4. WIPO Patent Application (2016). Method For The Treatment Of Malignancies. WO 2016/154473 A1.

5. WIPO Patent Application (2016). Camelid Single-domain Hcv Antibodies And Methods Of Use. WO 2016/172121 A1.